I don't think the sale of the generic division affects those not manufactured by MNK. Its mainly their oxy product and others they manufacture. From the way I read it those not manufactured by MNK are business as usual.
Doesn't mean theyre doing well.. but they're not getting sold.
Seeing that the oxy product is their best generic is likely why they are having a hard time finding bidders.
News 
Market Data 
Discover 
AI
